Dividend income offers a great way to strengthen your overall financial position. It can potentially make you less dependent on the income you earn from a job, maybe even allowing you to work less or retire earlier than planned. Money doesn't buy happiness, but being less dependent on work to fund your lifestyle could be a contributor to a happier, less stressful life.A great way to build up dividend income is to invest in high-yielding dividend stocks that also happen to be lower-risk investments. Pfizer ( ...

Core Insights - The wide moat strategy focuses on investing in companies with durable competitive advantages that ensure long-term profitability and market leadership [1][2] Group 1: Pfizer Inc. (PFE) - Pfizer is a leading drugmaker in oncology, bolstered by the acquisition of Seagen, which generated $3.4 billion in sales for 2024, reflecting a 38% increase on a pro forma basis [6] - The company has committed resources to develop treatments in oncology, internal medicine, immunology, inflammation, and vaccines, with new gene therapies for hemophilia gaining approval in 2024 [7] - Pfizer anticipates cost cuts and restructuring to save $7.7 billion by the end of 2027, alongside growth in non-COVID sales driving profit growth [8] - Expected revenue and earnings growth rates for Pfizer are 0.6% and 1% respectively for the current year, with a 3.4% improvement in the Zacks Consensus Estimate for earnings over the last 30 days [9] - Pfizer's forward P/E is 7.41X, significantly lower than the industry average of 12.96X and the S&P 500's 19.20X [10] - The average price target for Pfizer indicates a potential increase of 23.7% from the last closing price of $23, with a maximum upside of 43.5% [11] Group 2: The Coca-Cola Co. (KO) - Coca-Cola has shown positive business trends, consistently beating expectations, supported by higher pricing strategies amid inflation [12] - The company's all-weather strategy aims for revenue growth in 2025, focusing on marketing, innovation, and revenue management [12] - Expected revenue and earnings growth rates for Coca-Cola are 2.4% and 2.8% respectively for the current year, with a stable Zacks Consensus Estimate for earnings [13] - The average price target for Coca-Cola suggests an increase of 11.1% from the last closing price of $71.93, indicating a maximum upside of 19.6% [14] Group 3: The Walt Disney Co. (DIS) - Disney reported steady fiscal 2025 results with year-over-year growth in revenues and earnings, although international park locations faced declines [15] - The company expects double-digit percentage growth in segment operating income for fiscal 2025, with ESPN achieving significant viewership growth [16] - Disney has transformed its streaming business into a profitable growth engine, reporting its first-ever Direct-to-Consumer operating profit in FY2024 [17] - Expected revenue and earnings growth rates for Disney are 3.8% and 15.1% respectively for the current year, with a 4.6% improvement in the Zacks Consensus Estimate for earnings [18] - The average price target for Disney indicates a potential increase of 10.9% from the last closing price of $112.66, with a maximum upside of 31.4% [19]

Market Overview - The S&P 500 has declined approximately 6% since the beginning of the year, with a more significant drop earlier in April when global tariffs were announced [1] - Despite a recent recovery, the risk of further market sell-offs remains [1] Investment Opportunities - Long-term investors may find buying opportunities in stocks that are down over 10% this year and trading at low earnings multiples, specifically Pfizer, PayPal, and Builders FirstSource [2] Pfizer - Pfizer's stock has decreased by 13% in 2025, with expectations of nearly unchanged or declining revenue for the year [3][4] - The company trades at a forward P/E multiple of less than 8 and aims to add $25 billion in revenue through in-house development and acquisitions despite potential losses of $18 billion from generics by the end of the decade [4] - Recent acquisitions, including oncology company Seagen, are expected to contribute up to $10 billion in revenue by the end of the decade [5] - Pfizer's mRNA pipeline is projected to generate between $10 billion and $15 billion by 2030, and the company has over 100 drug candidates in clinical trials [6] - The stock offers a dividend yield of over 7%, making it an attractive long-term investment [7] PayPal - PayPal's stock is down more than 20% this year and trades at only 13 times its future earnings, with concerns about a global economic slowdown affecting its growth prospects [8] - The company holds a significant position in the global payments market, accounting for nearly 45% of it, and is well-positioned for long-term recovery [9] - PayPal is expanding into the crypto market with the launch of PayPal USD, offering a 3.7% yield to attract investors, which could drive more transactions and revenue growth [10] - The company's payment volume rose by 10% last year, indicating potential for long-term investment despite short-term concerns [11] Builders FirstSource - Builders FirstSource trades at a forward P/E of less than 13 and plays a vital role in the homebuilding industry [12] - The company experienced a 4% decline in sales in 2024, totaling $16.4 billion, but is expected to benefit from long-term housing market growth [13] - Builders FirstSource has grown significantly from $8.6 billion in sales in 2020, aided by acquisitions and a strong housing market [14] - The company invested $352 million in 13 acquisitions last year and projects a net sales growth of 4% to 4.5% from these acquisitions [15] - Despite a 15% decline in stock price this year, Builders FirstSource remains a strong long-term investment [16]